Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$208.38
-$1.97(-1.10%)
At close: 4:00 PM EST
$208.38
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$184.63 - $261.64
Previous CloseN/A
Volume1.02M
Average Volume (3M)7.72M
Market Cap
$449.63B
Enterprise Value$449.34K
Total Cash (Recent Filing)$9.39B
Total Debt (Recent Filing)$72.86B
Price to Earnings (P/E)124.8
Beta0.10
Next Earnings
Jul 31, 2026EPS Estimate
3.6Next Dividend Ex-DateN/A
Dividend Yield2.68%
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume6,492,493
30 Day Avg. Volume7,724,964
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$273.25Price Target Upside31.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)14.05
Revenue Forecast (FY)$67.32B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthConsistently strong operating and free cash flow provide durable internal funding for R&D, manufacturing capacity, dividends and M&A. This high cash conversion supports strategic investments and capital returns even with near-term margin noise, underpinning long-term execution flexibility.
Immunology Commercial MomentumRobust double-digit growth for Skyrizi and Rinvoq reflects expanding indications and market share, providing a multi-year revenue runway. Durable adoption across psoriasis, IBD and other indications strengthens AbbVie's franchise base and helps offset legacy Humira erosion over the medium term.
Pipeline And BD Expansion (Apogee Deal)Acquiring Apogee adds late-stage IL-13 and combination respiratory assets, materially deepening immunology leadership. While accretive only longer term, the deal structurally enhances future growth optionality and diversifies the product funnel beyond current franchises.
Bears Say
High LeverageVery large debt load relative to equity constrains financial flexibility and increases vulnerability to margin or revenue shocks. High leverage raises refinancing and interest coverage risk, limiting ability to rapidly reallocate capital or pursue large deals without pressuring credit metrics over the medium term.
Compressed Net MarginMaterial decline in net margin despite high gross margin indicates non-operating costs, acquired IPR&D charges and other items are eroding bottom-line conversion. Persistently lower net margin reduces retained earnings for debt paydown, weakens resilience to future shocks and slows balance-sheet repair.
Legacy Product Erosion And Execution RiskSharp Humira biosimilar erosion and pressure in parts of oncology and aesthetics create ongoing revenue replacement needs. Combined with clinical failures and non-differentiation in some programs, this raises execution risk that next-generation launches must meet to sustain long-term growth and offset legacy declines.
AbbVie News
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $184.63 and its highest was $261.63 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $449.63B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 31, 2026 which is in 10 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 29, 2026. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.592 by $0.058.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.68%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.6.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,792,800 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.592. Following the earnings report the stock price went up 3.136%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$273.25 (31.13% Upside)
$273.25 (31.13% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.08%
12-Months-Change
Fundamentals
Return on Equity
2.68%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$273.25
▲(31.13% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.80% Mutual Funds
― Other Institutional Investors
57.11% Public Companies and Individual Investors